Nava Therapeutics Emerges With $89M for Precision RNA-LNP Delivery

Company Nava Therapeutics Event Type $89 million financing disclosure (preclinical-stage company) Modality Extrahepatic RNA-lipid nanoparticle (LNP) delivery platform Platform Switch LNP: modular, tissue-selective ionizable lipids for in vivo CAR-T and renal gene editing Indication B-cell malignancies and autoimmune disease; chronic kidney disease (initial focus areas)…